RxDoctor Payments Data

Rajul Patel, MD

Cardiovascular Disease · Glendale, AZNPI 1225024318

Payments from drug & device makers

$16,794in general payments, 2019–2025

Across 695 payments — averaging $24.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$4K
  • Novartis$2K
  • Amgen$1K
  • Cook Research Incorporated$1K
  • Abiomed$921
  • Boehringer Ingelheim$675
  • plus $7K from 41 others

What the payments were for

  • Travel & lodging$7266%
  • Food & beverage$10,76491%
  • Education$2762%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,794 in reported general payments places this provider in the 80th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona

Medicare billing

Part B allowed, 2024
$827,230
Medicare patients
872
Services billed
3,900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban133$136,288
EntrestoSacubitril/Valsartan98$132,541
XareltoRivaroxaban42$47,121
FarxigaDapagliflozin Propanediol45$43,170
Repatha SureclickEvolocumab60$38,924
JardianceEmpagliflozin18$19,152
Ranolazine ErRanolazine14$1,861
Rosuvastatin Calcium117$1,641
Ezetimibe82$1,489
Metoprolol Succinate120$1,411
ClopidogrelClopidogrel Bisulfate120$1,252
Atorvastatin Calcium103$1,106
Carvedilol89$578
Losartan Potassium37$324
Furosemide59$269

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$175$136,288133 claims
NovartisEntresto$1,804$132,54198 claims
Johnson & JohnsonXarelto$243$47,12142 claims
AstraZenecaFarxiga$339$43,17045 claims
Boehringer IngelheimJardiance$675$19,15218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 423 cardiovascular disease providers in Arizona.

Other cardiovascular disease in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →